237 related articles for article (PubMed ID: 22904682)
1. Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer.
Jackson RS; Placzek W; Fernandez A; Ziaee S; Chu CY; Wei J; Stebbins J; Kitada S; Fritz G; Reed JC; Chung LW; Pellecchia M; Bhowmick NA
Neoplasia; 2012 Jul; 14(7):656-65. PubMed ID: 22904682
[TBL] [Abstract][Full Text] [Related]
2. Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity.
Dash R; Azab B; Quinn BA; Shen X; Wang XY; Das SK; Rahmani M; Wei J; Hedvat M; Dent P; Dmitriev IP; Curiel DT; Grant S; Wu B; Stebbins JL; Pellecchia M; Reed JC; Sarkar D; Fisher PB
Proc Natl Acad Sci U S A; 2011 May; 108(21):8785-90. PubMed ID: 21555592
[TBL] [Abstract][Full Text] [Related]
3. Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer.
Hu Y; Yagüe E; Zhao J; Wang L; Bai J; Yang Q; Pan T; Zhao H; Liu J; Zhang J
Cancer Lett; 2018 Jun; 423():47-59. PubMed ID: 29496539
[TBL] [Abstract][Full Text] [Related]
4. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.
Meng Y; Tang W; Dai Y; Wu X; Liu M; Ji Q; Ji M; Pienta K; Lawrence T; Xu L
Mol Cancer Ther; 2008 Jul; 7(7):2192-202. PubMed ID: 18645028
[TBL] [Abstract][Full Text] [Related]
5. In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration.
Loberg RD; McGregor N; Ying C; Sargent E; Pienta KJ
Neoplasia; 2007 Dec; 9(12):1030-7. PubMed ID: 18084610
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells.
Zhang S; Zhau HE; Osunkoya AO; Iqbal S; Yang X; Fan S; Chen Z; Wang R; Marshall FF; Chung LW; Wu D
Mol Cancer; 2010 Jan; 9():9. PubMed ID: 20085644
[TBL] [Abstract][Full Text] [Related]
7. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
8. Mcl-1 is an important therapeutic target for oral squamous cell carcinomas.
Maji S; Samal SK; Pattanaik L; Panda S; Quinn BA; Das SK; Sarkar D; Pellecchia M; Fisher PB; Dash R
Oncotarget; 2015 Jun; 6(18):16623-37. PubMed ID: 26009874
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer.
Sonpavde G; Matveev V; Burke JM; Caton JR; Fleming MT; Hutson TE; Galsky MD; Berry WR; Karlov P; Holmlund JT; Wood BA; Brookes M; Leopold L
Ann Oncol; 2012 Jul; 23(7):1803-8. PubMed ID: 22112969
[TBL] [Abstract][Full Text] [Related]
10. Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic.
Sarkar S; Quinn BA; Shen XN; Dash R; Das SK; Emdad L; Klibanov AL; Wang XY; Pellecchia M; Sarkar D; Fisher PB
Oncotarget; 2015 May; 6(13):10712-27. PubMed ID: 25926554
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation.
Lian J; Ni Z; Dai X; Su C; Smith AR; Xu L; He F
Mol Cancer Ther; 2012 Feb; 11(2):416-26. PubMed ID: 22188816
[TBL] [Abstract][Full Text] [Related]
12. Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity.
Placencio VR; Sharif-Afshar AR; Li X; Huang H; Uwamariya C; Neilson EG; Shen MM; Matusik RJ; Hayward SW; Bhowmick NA
Cancer Res; 2008 Jun; 68(12):4709-18. PubMed ID: 18559517
[TBL] [Abstract][Full Text] [Related]
13. Preclinical studies of apogossypolone, a novel pan inhibitor of bcl-2 and mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells.
Banerjee S; Choi M; Aboukameel A; Wang Z; Mohammad M; Chen J; Yang D; Sarkar FH; Mohammad RM
Pancreas; 2010 Apr; 39(3):323-31. PubMed ID: 19823097
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
[TBL] [Abstract][Full Text] [Related]
15. β-elemonic acid inhibits growth and triggers apoptosis in human castration-resistant prostate cancer cells through the suppression of JAK2/STAT3/MCL-1 and NF-ĸB signal pathways.
Bao X; Zhu J; Ren C; Zhao A; Zhang M; Zhu Z; Lu X; Zhang Y; Li X; Sima X; Li J; Zhang Q; Ma B
Chem Biol Interact; 2021 Jun; 342():109477. PubMed ID: 33878321
[TBL] [Abstract][Full Text] [Related]
16. Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction.
Najy AJ; Jung YS; Won JJ; Conley-LaComb MK; Saliganan A; Kim CJ; Heath E; Cher ML; Bonfil RD; Kim HR
Prostate; 2012 Sep; 72(12):1328-38. PubMed ID: 22213159
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative.
Zhang S; Gera L; Mamouni K; Li X; Chen Z; Kucuk O; Wu D
Oncotarget; 2016 May; 7(19):27489-98. PubMed ID: 27050371
[TBL] [Abstract][Full Text] [Related]
18. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
Hwang JJ; Kim YS; Kim T; Kim MJ; Jeong IG; Lee JH; Choi J; Jang S; Ro S; Kim CS
Invest New Drugs; 2012 Aug; 30(4):1434-42. PubMed ID: 21773733
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145.
Kucukzeybek Y; Gul MK; Cengiz E; Erten C; Karaca B; Gorumlu G; Atmaca H; Uzunoglu S; Karabulut B; Sanli UA; Uslu R
J Exp Clin Cancer Res; 2008 Sep; 27(1):37. PubMed ID: 18789152
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer.
Banerjee S; Hussain M; Wang Z; Saliganan A; Che M; Bonfil D; Cher M; Sarkar FH
Cancer Res; 2007 Apr; 67(8):3818-26. PubMed ID: 17440096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]